Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Anyone care to comment on below lawsuit? The one thing that nags at me is why we do not see more adoption of AR? I sense it takes a lot of work to implement the technology. I was thrilled to see New Balance sign up but where is the AR?
https://www.newbalance.ca/en_ca/pd/fresh-foam-roav/MROAVV1-25000-M.html?dwvar_MROAVV1-25000-M_style=MROAVLW#style=MROAVLW
https://www.businesswire.com/news/home/20200210005815/en/EQUITY-ALERT-Rosen-Law-Firm-Announces-Investigation
Thanks for this. Puts my mind at ease; however, still a little concerned over small gold company’s CFO not knowing they signed up to do business with NexTech. I was a little surprised the CFO answered the phone and I assume he would know if the CEO farted-Let alone who they do business with. I may take the plunge again and will mull this over.
Wrightbrothers is using this works when you click on AR logo.
https://www.thewrightbrothersusa.com/products/st-clair-1896-alfine-8-adventure-bicycle
So here is link to Jumpball
https://www.jumpballapparel.com/product-page/jumpers
Could not find any ar applications. Please prove me wrong because I still find this hard to believe. Does anyone know how long it takes to get set up and implement? I've been very impressed with the volume of clients. I did DD in early stages but I'm not so sure now.
Says New Balance using them but appears only one part of their website using their technology and doesn't work the way I expect it to.
https://www.newbalance.ca/en_ca/pd/nb1-997-sport/M997CS1-BLANK.html?ICID=PN_8727_M
If anyone can, please provide website link showing full use of their platform. The Bay, Amazon or Sport Chek should be using their platform.
I am too, I hope they respond to this report. I admit it spooked me. I am going to email NexTech. I wonder if they will respond to it on-line? I really believe in the technology and what they are doing. I know some of these reports are shorters and not to be believed. I did not sell my CYDY investment after a report; even though, it took quite a hit.
He told me they don't do business with NexTech never heard of them. I told him there was a press release they do. That was the end of it. I was planning on adding to my TFSA, sold some open investments and planned to transfer to my TFSA. I'm really lost here.
I called Romios Gold and spoke to CFO (416-221-4124) advised no connection to NexTech AR. I sold based on that conversation. I am not happy. I really like the name. I bought a small position on a hunch. I used to work near their office on Carlaw Avenue in Toronto. I hope the report is wrong. I will buy back in if so. Some of it made sense. How could the CFO not know of a deal?
I believe it helps the share price that Christine Corrado does the interviews. I have a crush on here. I hope NP responds to the dropping share price and tells us exactly where we are with the BLA submission. He has to start meeting deadlines or stop overpromising.
Yes, the Culper Report was a hit job-All anonymous. Do you really believe very busy MDs would take time out of their day to speak to someone who wants to short stocks to make a quick profit? It should also be noted that Emerging Growth was compensated $2,500 by CYDY-Your money.
EmergingGrowth.com has been compensated two thousand five hundred dollars in consideration for its work with CytoDyn, Inc. through the date this was published. EmergingGrowth.com may or may not receive additional compensation, details about which can be found in our full disclosure, which can be found here, https://emerginggrowth.com/68272-2939/. You can easily loose money investing in highly speculative small cap stocks like the ones mentioned within. Please consult an investment professional before investing in anything viewed within. When EmergingGrowth.com is long shares it will sell those shares. In addition, please make sure you read and understand the Terms of Use, Privacy Policy and the Disclosure posted on the EmergingGrowth.com website.
Reposting links did not work.
CYDY needs to start meeting some timelines. Time is money. See below example from end of year 2015 Nader Pourhassan being interviewed by his daughter (I assume) Morvarid Pourhassan. CEO advises he hopes to be commercial with his adjunct therapy in 2017.
CYDY needs a partner. They need money. They need a bigger team. If you want to accelerate Leronlimab in HIV and fully explore cancer and NASH, you need deeper resources and deeper pockets. If you want to move forward faster, you need to make sacrifices.
CYDY needs to start meeting some timelines. Time is money. See below example from end of year 2015 Nader Pourhassan being interviewed by his daughter (I assume) Morvarid Pourhassan. CEO advises he hopes to be commercial with his adjunct therapy in 2017.
www.youtube.com/...
CYDY needs a partner. They need money. They need a bigger team. If you want to accelerate Leronlimab in HIV and fully explore cancer and NASH, you need deeper resources and deeper pockets. If you want to move forward faster, you need to make sacrifices.
I believe the CEO and many of his senior members are running out of steam. They need to look in the mirror and admit they need help. Make a deal and get the BLA submitted.
Unfortunately, the delay in the BLA along with the report by someone shorting the stock has hurt the share price. I asked Culper many questions with no response and he has deleted responses to his Twitter account by many posters. 'Will the author of this report hiding behind a disclaimer and pseudonym respond to below?
“In our view, CytoDyn’s chief claim to advantageous treatment vs. existing options are its form, being a once-weekly injection as opposed to once or twice-daily pills. It remains unclear to us whether or not self-administration of injections would in fact improve adherence, but in either case, major pharmaceutical companies such as GlaxoSmithKline are already besting CytoDyn’s once-weekly injection with a once-monthly injection.”
It is not being bested, as the FDA rejected this. See below from a real news organization.
www.bloomberg.com/... '
Dr. Jonah Sacha is scheduled to give a presentation on Leronlimab at the Keystone Symposia on HIV Pathogenesis and Cure in Keystone, Colorado on March 26. For some reason the link disappeared from CytoDyn’s website. If Leronlimab is a hoax as Culper suggests, why on God’s Green Earth would Dr. Jonah Sacha be involved with CYDY? Why would Dr. Bruce Patterson be involved? Why would Dr. Richard Pestell have been involved? Why would everyone tied into the trials be involved? Would the FDA not have caught on by now?
www.globenewswire.com/...
What I want to hear from Thursday’s meeting is more info about the Emergency Type C Meeting with the FDA and the 50 patients to be treated. Will they be treated with just Leronlimab? When will the FDA meet to discuss this? Says they have 75 days to meet. I assume some patients cannot wait that long? How quickly will patients be treated should FDA authorize this? Where are these patients? Where will the treatments occur?
Does anyone know where we are in regards to below?
https://clinicaltrials.gov/ct2/show/NCT03838367
I assume below will take precedence?
https://www.cytodyn.com/newsroom/press-releases/detail/380/cytodyn-announces-stunning-results-from-clinical-trials
This is the year the CYDY plane will land. We’re all circling the airport at the moment. There will either be a buyout or licensing deal-As soon as we start to get more and more favorable results treating cancer. The age of Alan Timmins, Brendan Rae, and Nader Pourhassan will work in our favour. They’re not going to want to wait 5 to 10 years to push through all the cancer indications funded via HIV treatments. I’m sure they will want to speed this up. I want to land in Vienna and live out my life there. I’m pushing 58. I’m sure most of their dreams have been realized but another fat paycheque would solidify whatever they want out of life with the years they have left. Happy landings to one and all! I expect good news on Thursday and closing in on $2 Friday. With luck, we will up list to Nasdaq this summer!
It could very well happen. If you had HIV and you had the option of a weekly injection with no side effects, what would you do? If you had cancer, would you want chemo, radiation, surgery or would you want Leronlimab? There are 18,000,000 cancer cases worldwide every year. Even if Leronlimab is only used for 25%, you’re easily looking at $2 or so trillion over 20-year patent life (at ballpark $25,000 per patient).
This is a fair assessment. I see SP of $20 easy for the entire HIV space. Yes, cancer is another world. As below article bemoans, billions spent with very little progress compared to the research. The quickest way to get there will be with a partner. I hope we find one to get us there faster to save lives faster. Once we get results for the additional patients being dosed, we will be closer to realizing higher SP-Assuming they are as promising as the first 2. Other key events will be BLA submission, FDA approval, and up listing to Nasdaq. That is when this thing will really take off.
https://www.cbc.ca/radio/thecurrent/the-current-for-jan-23-2020-1.5437375/cancer-research-is-an-embarrassment-must-switch-focus-to-early-detection-oncologist-1.5437378
Imagine this question on Jeopardy!
This humanized monoclonal antibody blocks the calcium channel signaling of the CCR5 receptor and has the potential to disable the GPS system.
Answer: What is Leronlimab?
Fantastic article!
In comparison, leronlimab is significantly safer than mariviroc and has hardly any drug related side effects reported from the 830 patients that were dosed. leronlimab keeps the virus outside the T-cell so that it can’t replicate. If the virus can’t replicate, it can’t mutate and this prevents patients from developing drug resistance, eliminating one of the key challenges doctors face when dealing with long term conditions. If CYDY can secure approval for leronlimab, it would essentially make all HAART drugs currently under development obsolete and give the company a key first mover advantage.
Luv this!
To conclude, I would like to reiterate a fitting quote from the recent corporate presentation:
"Sometimes it is the people no one can imagine anything of who do the things no one can imagine."
– Alan Turing
“Vyera will pay upfront, regulatory and sales-based milestone payments totaling up to $87.5 million, as well as a royalty on net sales of 50%. Additionally, Vyera will purchase $4 million of CytoDyn common stock.”
https://www.globallegalchronicle.com/vyera-pharmaceuticals-commercialization-agreement-with-cytodyn/
We closed at a dollar up 7.52%! Congrats to the team at CYDY for getting the sales deal done! Next events that will boost share price are obviously BLA submission, FDA approval, and updates on the cancer space. I only own 21,500 shares, which is a lot for me. I invested okay with it going to zero and I’m pretty damn sure that is not going to happen. I know some are upset that they missed the train or sold too early but we all know even if we just have all components of the HIV, that is going to be huge. That is the key for me, as it will legitimatize Leronlimab and get people to thinking about what it can do for cancer. Happy New Year to everyone! I am holding on for the ride.
https://www.marketwatch.com/investing/stock/cydy
I’m buckling up and look forward to the ride!
Do you smell what the Nader is cooking?
I believe that has been the problem all along for the share price-OTC. I own 21,500 shares ALL in my open account. My broker (likely following Canada Revenue Agency guidelines) will not allow me to purchase shares in my RRSP or TFSA. I know many people, who only follow the big exchanges.
Once the BLA is submitted, perhaps it will inch closer to a dollar at some point and then the next needle mover will be approval. By early summer, I hope we hit $2. I suspect the approval will create a flood of media exposure given that Charlie Sheen is on Leronlimab along with the history of our sales company with Pharma Bro (no idea if he still owns shares). Perhaps this will work in our favour? I’m sure Vyera wants this to be successful and you can bet Pharma Bro likewise.
I can see Nader Pourhassan on some nationally televised talk show discussing the deal and how everyone closed door after door in his face and now he has a life changing FDA approved product. More and more people are taking control of their healthcare. If I had HIV, I would start googling for my best options and this certainly appears to be a great option (once a week injectable with little or zero side effects).
Maybe one day we will see CYDY at the Nasdaq Bell Ringing Ceremony?
See this interview from August 2018 4-minute mark appears there was a cut. I do not believe he would be allowed to mention the name of company while on the trail or off trail and taking drug. This is what tipped me over to buy. Charlie Sheen looks very healthy indeed. I don’t even think we’ve touched the surface yet. There could be a lot more to come. This is just the start.
Luv the fact the deal is for 50% royalties. That sets a precedent for other deals. I can’t wait to see NP on some news program touting the benefits of Leronlimab and telling the world how many doors were slammed in his face for a licensing deal! Fact, is one door opened, he walked in and we have a deal. I bet you the team at Vyera Pharmaceuticals is very excited to sell Leronlimab and they will want this to be a huge success. I suspect they have the money and will beef up their team. They will knock Leronlimab out of the park!
www.youtube.com/watch?v=zDRSDlsPcKQ
I too was disappointed in choice but money is money-We have a deal maybe with the devil but I don’t care. I want to make money and save lives while I’m at it. In the end, I don’t think it matters if Pharma Bro is running this company because all that really matters is the science and FDA approval for the BLA. Most of my friends do their own due diligence for healthcare for the best treatment possible. If you had HIV, you would google and find Leronlimab along with the Charlie Sheen story. Once a week injection with little to zero side effects. What’s not to love about that?
Yes.
I believe CYDY will make headlines for many reasons. I am very confident they will be very successful in the HIV space and Cancer, etc. is only a matter of time. https://www.businessinsider.com/r-company-founded-by-shkreli-off-the-hook-in-43-million-lawsuit-judge-2017-9
According to Biocentury, Vyera Pharmaceuticals, raised $90 mil in financing. According to press release, CYDY will receive up to $87.5 mil in sales-based milestone payments along with the $4 mil purchase of CYDY stock. I believe they have the money along with a Sales Team, which will likely be beefed up.
NP essentially stated the new company has nothing to do with Martin Shkreli, infamous for securities fraud along with boosting price of Daraprim to $750 per pill. It should be noted Biocentury reports Vyera paid $55 mil for the U.S. rights. I must assume they need to make their money back on this payment. According to below website: “On average, Medicaid programs in 2017 paid $35,556.48 per Daraprim prescription, according to a Kaiser Health News analysis of federal data covering that year’s first three quarters.” 2,000 in U.S. quoted as needing this drug = $71 mil per year. Deal completed in August of 2015 = Ballpark $300 mil.
• Does anyone know if Mr. Shkreli still owns shares in Vyera? If BLA approved for HIV, sales go well and cancer applications look promising, maybe they will buy CYDY?
https://bciq.biocentury.com/companies/vyera_pharmaceuticals_llc
khn.org/news/for-shame-pharma-bro-shkreli-is-in-prison-but-daraprims-price-is-still-high/
The Blue Baron and Blue Horseshoe love Cytodyn!
Imagine for a moment, Leronlimab was developed by J&J-We all know the HIV would already be priced in along with maybe 25% of the cancer applications. I’m sure everyone who invested in this stock was perhaps a little desperate and hungry willing to give up risk for a big return. That’s what stood out for me in the Proactive interview. Nader used the word hungry to describe Vyera Pharmaceuticals and CytoDyn. I like people who are hungry. They want to go somewhere. They want to better themselves and they want to better the people around them. That is the environment I want to be in. I’m feeling really good about CYDY and the share price is showing it. Sometimes a Cassius Clay will emerge to upset a Sonnie Liston. Gilead will be sweating should the BLA be approved. How much money will you make invested in a company sitting on its laurels, who is embroiled in a lawsuit? Answer: Not much if anything.
Assuming insurance covers. Far fewer side effects. I would lower the cost. In any case, we will find a space for this.
The key for me is approval of the BLA. At that point, the clock will start ticking for Gilead, ViiV, etc. Ballpark 1.1 mil are living with HIV in the U.S. Let’s say Leronlimab is appropriate and used for just 10% of those people, you’re looking at 110,000 mil x $60,000 = $6.6 bil 50% royalty = $3.3 bil. There are ballpark 38 mil living with HIV in the world. I assume a much lower pricing model would be used for nations like Africa.
I assume most Americans would start googling as soon as they suspected or were advised they had HIV and would find Leronlimab and would seriously look at this as a course of treatment. One injection once per week with virtually no side effects versus pills every day with side effects.
I wish we had a different sales company; however, once the money starts rolling in, I’m sure they will increase their sales force and many will find Leronlimab on their own and ask their doctor about it.
http://theconversation.com/south-africa-needs-to-get-more-young-people-with-hiv-on-treatment-125591
37 cents and climbing!